Safety of high-dose doripenem in adult patients with cystic fibrosis
Open Access
- 8 April 2016
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 7 (3) , 89-93
Abstract
High doses of β-lactam antibiotics have been advocated for acute pulmonary exacerbations caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF) secondary to high minimum inhibitory concentrations (MIC) of the infecting organisms. Some β-lactam antibiotics have increased elimination in CF patients. This case series examines the safety of high-dose doripenem (HDD), 2 g intravenously every 8 hours, which is 4 times the labeled dose, in CF patients. This was a retrospective, single site, chart review of all CF patients given HDD during a 3-year period. Adverse events were prospectively defined using labeled definitions within the package insert and the medical literature. A standard case report form was used to collect demographic details, antibiotic lengths of therapy and adverse events. A total of 17 patients (9 males), with a median age of 24 years, contributed 43 unique visits and 382 HDD exposure days. Mean duration of inpatient doripenem use was 8.9 days. Concurrent antibiotics were common, with a median number of additional antibiotics per admission of three. The median number of adverse effects documented was two. The most common adverse event was anemia, which was identified in 41 of 43 visits, but was present on admission in 31 instances. One patient developed leukopenia for 1 day, but returned to normal without dose adjustment. There were three instances of Clostridium difficile infection. One patient was documented to have an allergic reaction that led to discontinuation, but was ultimately rechallenged without adverse effect. Other common adverse events were gastrointestinal in origin. No other possible adverse effects led to discontinuation of the drug. In adult patients with CF, HDD in combination with other antibiotics did not lead to adverse effects necessitating discontinuation. HDD should be considered in this selected patient population, particularly when high MIC organisms are identified.Keywords
This publication has 21 references indexed in Scilit:
- The Use of Doripenem in Pediatric Cystic Fibrosis Patients in Case of Meropenem ShortagesPediatric Pulmonology, 2013
- Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a reviewEuropean Journal of Clinical Microbiology & Infectious Diseases, 2013
- Adverse reactions to β-lactam antimicrobialsExpert Opinion on Drug Safety, 2012
- Epileptogenic Potential of Carbapenem Agents: Mechanism of Action, Seizure Rates, and Clinical ConsiderationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
- Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Doripenem: A New Carbapenem in the Treatment of Nosocomial InfectionClinical Infectious Diseases, 2009
- Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.Diagnostic Microbiology and Infectious Disease, 2009
- Anemia in Cystic Fibrosis: Incidence, Mechanisms, and Association With Pulmonary Function and Vitamin DeficiencyNutrition in Clinical Practice, 2008
- Carbapenems: a potent class of antibioticsExpert Opinion on Pharmacotherapy, 2007
- In Vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis PatientsAntimicrobial Agents and Chemotherapy, 2006